Other News To Note
Tuesday, July 12, 2011
Poniard Pharmaceuticals Inc., of San Francisco, adjourned its annual meeting until July 22 to get additional proxies to approve a reverse stock split in the range of 1-for-15 to 1-for-25 to regain compliance with Nasdaq's minimum $1 bid requirement. If the proposal isn't approved, the company said it could impact completion of its merger agreement with privately held Allozyne Inc., of Seattle.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.